These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 17706531)

  • 1. Detection of bone metastases in breast cancer by positron emission tomography.
    Schirrmeister H
    Radiol Clin North Am; 2007 Jul; 45(4):669-76, vi. PubMed ID: 17706531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Bone Metastases in Breast Cancer by Positron Emission Tomography.
    Schirrmeister H
    PET Clin; 2006 Jan; 1(1):25-32. PubMed ID: 27156956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer.
    Nakai T; Okuyama C; Kubota T; Yamada K; Ushijima Y; Taniike K; Suzuki T; Nishimura T
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1253-8. PubMed ID: 16133397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer.
    Uematsu T; Yuen S; Yukisawa S; Aramaki T; Morimoto N; Endo M; Furukawa H; Uchida Y; Watanabe J
    AJR Am J Roentgenol; 2005 Apr; 184(4):1266-73. PubMed ID: 15788608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET.
    Huyge V; Garcia C; Vanderstappen A; Alexiou J; Gil T; Flamen P
    Clin Nucl Med; 2009 Jul; 34(7):417-20. PubMed ID: 19542943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions.
    Cook GJ; Houston S; Rubens R; Maisey MN; Fogelman I
    J Clin Oncol; 1998 Oct; 16(10):3375-9. PubMed ID: 9779715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis: comparison of F-18 Fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer.
    Shie P; Cardarelli R; Brandon D; Erdman W; Abdulrahim N
    Clin Nucl Med; 2008 Feb; 33(2):97-101. PubMed ID: 18209527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer.
    Abe K; Sasaki M; Kuwabara Y; Koga H; Baba S; Hayashi K; Takahashi N; Honda H
    Ann Nucl Med; 2005 Oct; 19(7):573-9. PubMed ID: 16363622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Heterogeneity of bone metastases in a patient with breast cancer: case report illustrating the potential of combining various imaging techniques].
    Withofs N; Collignon J; Rorive A; Jerusalem G; Hustinx R
    Rev Med Liege; 2011; 66(5-6):288-90. PubMed ID: 21826964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-avid sclerotic bone metastases in breast cancer patients: a PET/CT case series.
    Koolen BB; Vegt E; Rutgers EJ; Vogel WV; Stokkel MP; Hoefnagel CA; Fioole-Bruining A; Vrancken Peeters MJ; Valdés Olmos RA
    Ann Nucl Med; 2012 Jan; 26(1):86-91. PubMed ID: 21953212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of metastases in breast cancer patients: comparison of FDG PET with chest X-ray, bone scintigraphy and ultrasound of the abdomen].
    Dose-Schwarz J; Mahner S; Schirrmacher S; Jenicke L; Müller V; Habermann CR; Brenner W
    Nuklearmedizin; 2008; 47(3):97-103. PubMed ID: 18493688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron emission tomography and bone metastases.
    Fogelman I; Cook G; Israel O; Van der Wall H
    Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer.
    Yang SN; Liang JA; Lin FJ; Kao CH; Lin CC; Lee CC
    J Cancer Res Clin Oncol; 2002 Jun; 128(6):325-8. PubMed ID: 12073051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET.
    Eubank WB; Mankoff DA; Vesselle HJ; Eary JF; Schubert EK; Dunnwald LK; Lindsley SK; Gralow JR; Austin-Seymour MM; Ellis GK; Livingston RB
    Radiographics; 2002; 22(1):5-17. PubMed ID: 11796893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of bone metastases from breast cancer by bone scintigraphy and positron emission tomography/computed tomography imaging.
    Pires AO; Borges US; Lopes-Costa PV; Gebrim LH; da Silva BB
    Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():138-41. PubMed ID: 25037283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (18)F-fluoride PET imaging in a nude rat model of bone metastasis from breast cancer: Comparison with (18)F-FDG and bioluminescence imaging.
    Kang WJ; Song EH; Park JY; Park YJ; Cho A; Song HT
    Nucl Med Biol; 2015 Sep; 42(9):728-33. PubMed ID: 26068116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
    Du Y; Cullum I; Illidge TM; Ell PJ
    J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors.
    Sugihara T; Koizumi M; Koyama M; Terauchi T; Gomi N; Ito Y; Hatake K; Sata N
    Ann Nucl Med; 2017 Dec; 31(10):719-725. PubMed ID: 28864931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.
    Mahner S; Schirrmacher S; Brenner W; Jenicke L; Habermann CR; Avril N; Dose-Schwarz J
    Ann Oncol; 2008 Jul; 19(7):1249-1254. PubMed ID: 18356138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.